Trial Profile

An observational clinical study for Camrelizumab in the treatment of inoperable lung cancer

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Antineoplastics
Indications Adenocarcinoma; Lung cancer; Small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

31 Jan 2021 Results (n=222) presented at the 2020 World Conference on Lung Cancer
31 May 2020 Status changed from not yet recruiting to recruiting as per results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results (N=97), subgroup analysis assessing antitumour activity and toxicity, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com